D. Yu. Frantsev
D. Yu. Frantsev has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Д. Ю. Францев
Национальный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава России
12 shared publications- Boris I. Dolgushin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
8 shared publications - Aleksandr N. Polyakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
7 shared publications - Eduard R. Virshke
N.N. Blokhin National Medical Research Center of Oncology
7 shared publications - Vladimir Yu. Pogrebnyakov
N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia
6 shared publications - Danila V. Podluzhnyi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
5 shared publications
Latest Publications
- 24 April 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 4,p. 22-31
Selection of drainage method for resectable cholangiocarcinoma complicated by obstructive jaundice
Objective. To compare the results of percutaneous and endoscopic biliary decompression for resectable perihilar tumor (PT). Material and methods. Treatment outcomes were analyzed in patients with PT who underwent surgery between 1999 and 2023. The 1st group included patients who underwent percutaneous transhepatic cholangiostomy as the first stage for biliary decompression, the 2nd group — patients who underwent endoscopic biliary drainage. Results. There were 58 patients with percutaneous transhepatic cholangiostomy and 18 ones with endoscopic biliary drainage. Both groups were comparable in main parameters. There were patients with isolated resection of extrahepatic bile ducts in the group of percutaneous transhepatic cholangiostomy, but these were absent in the 2nd group (p=0.328). Extended right-sided hemihepatectomies were more common in the 1st group (29.3% versus 11.1%, p=0.210). Post-manipulation complications grade ≥ III degree more common after endoscopic biliary drainage (50.0% versus 22.4%, p=0.037), and percutaneous cholangiostomy was also more common to correct complications (44.4% versus 10.3%, p=0.003). There was no difference in the rate of post-resection complications grade ≥III (p=0.787) and postoperative mortality (p=0.721). There was also no difference in peritoneal metastases (p=1.0) and implantation metastases (p=1.0). In addition, we found no worsening of long-term results after percutaneous transhepatic cholangiostomy. The median overall survival in this group was 25 months versus 15 months after endoscopic biliary drainage (p=0.740). There was also no difference in disease-free survival (p=0.500). Conclusion. Percutaneous transhepatic cholangiostomy as the primary method for obstructive jaundice in patients with resectable PT is accompanied by better immediate results of biliary decompression without worsening the results of resection.
- 24 April 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 4,p. 22-31
Selection of drainage method for resectable cholangiocarcinoma complicated by obstructive jaundice
Objective. To compare the results of percutaneous and endoscopic biliary decompression for resectable perihilar tumor (PT). Material and methods. Treatment outcomes were analyzed in patients with PT who underwent surgery between 1999 and 2023. The 1st group included patients who underwent percutaneous transhepatic cholangiostomy as the first stage for biliary decompression, the 2nd group — patients who underwent endoscopic biliary drainage. Results. There were 58 patients with percutaneous transhepatic cholangiostomy and 18 ones with endoscopic biliary drainage. Both groups were comparable in main parameters. There were patients with isolated resection of extrahepatic bile ducts in the group of percutaneous transhepatic cholangiostomy, but these were absent in the 2nd group (p=0.328). Extended right-sided hemihepatectomies were more common in the 1st group (29.3% versus 11.1%, p=0.210). Post-manipulation complications grade ≥ III degree more common after endoscopic biliary drainage (50.0% versus 22.4%, p=0.037), and percutaneous cholangiostomy was also more common to correct complications (44.4% versus 10.3%, p=0.003). There was no difference in the rate of post-resection complications grade ≥III (p=0.787) and postoperative mortality (p=0.721). There was also no difference in peritoneal metastases (p=1.0) and implantation metastases (p=1.0). In addition, we found no worsening of long-term results after percutaneous transhepatic cholangiostomy. The median overall survival in this group was 25 months versus 15 months after endoscopic biliary drainage (p=0.740). There was also no difference in disease-free survival (p=0.500). Conclusion. Percutaneous transhepatic cholangiostomy as the primary method for obstructive jaundice in patients with resectable PT is accompanied by better immediate results of biliary decompression without worsening the results of resection.
- Open Access
- 3 September 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (3) , 68-74
Induction chemotherapy regimens in malignant trophoblastic tumors with high risk of resistance: retrospective study
Background. High sensitivity of gestational throphoblastic disease (GTD) to chemotherapy makes this disease highly curable, but rapid destruction of tumor can lead to development of life-threatening complications. Low-dose chemotherapy before the main anticancer treatment can reduce these risks, but the effects on long-term outcomes are not sufficiently studied. We conducted a retrospective analysis of the N . N . Blokhin National Medical Research Center of Oncology experience in treating patients with high- and ultra-high risk GTD treated with low-dose induction or full-dose chemotherapy.Materials and methods. The monocenter comparative retrospective study included patients with high or ultra-high risk GTD who received initial treatment in 2000–2023. Patients with rare GTD subtypes, patients who had previously received any chemotherapy were excluded. Patients who received low-dose induction chemotherapy with etoposide + cisplatin comprised the experimental group, while those who received full-dose chemotherapy comprised the control group. After completion of low-dose chemotherapy, standard multidrug chemotherapy was administered until normalization of serum beta human chorionic gonadotropin (β-hCG), followed by consolidation chemotherapy. The primary endpoint of the study was 1-year progression-free survival.Results. The study included 70 patients with GTD, 21 (30 %) patients received low-dose induction chemotherapy. In this group, more patients had ECOG performance status ≥2, clinically significant bleeding, or central nervous system metastases. With median follow-up of 54.6 months, 1-year progression-free survival was 81 % in the low-dose induction chemotherapy group and 90 % in the control group, the differences were not statistically significant (hazard ratio 1.63; 95 % confidence interval 0.46–5.80; p = 0.447). Complete β-hCG response was noted in 16 (77 %) patients in the lowdose induction group and 43 (88 %) patients in control group (p = 0.231). Three-year overall survival rates were 95 % and 98 %, respectively.Conclusion. The results of this retrospective study show no differences in survival of patients with high-risk and ultra-highrisk GTD receiving low-dose induction chemotherapy. In treatment of patients with high risks of complications due to tumor process and/or drug therapy, low-risk induction chemoterhapy should be considered as an option
- 3 September 2025
- Published by N.N. Blokhin Cancer Fund in Surgery and Oncology
- Vol. 15 (3) , 68-74
Open AccessInduction chemotherapy regimens in malignant trophoblastic tumors with high risk of resistance: retrospective study
Background. High sensitivity of gestational throphoblastic disease (GTD) to chemotherapy makes this disease highly curable, but rapid destruction of tumor can lead to development of life-threatening complications. Low-dose chemotherapy before the main anticancer treatment can reduce these risks, but the effects on long-term outcomes are not sufficiently studied. We conducted a retrospective analysis of the N . N . Blokhin National Medical Research Center of Oncology experience in treating patients with high- and ultra-high risk GTD treated with low-dose induction or full-dose chemotherapy.Materials and methods. The monocenter comparative retrospective study included patients with high or ultra-high risk GTD who received initial treatment in 2000–2023. Patients with rare GTD subtypes, patients who had previously received any chemotherapy were excluded. Patients who received low-dose induction chemotherapy with etoposide + cisplatin comprised the experimental group, while those who received full-dose chemotherapy comprised the control group. After completion of low-dose chemotherapy, standard multidrug chemotherapy was administered until normalization of serum beta human chorionic gonadotropin (β-hCG), followed by consolidation chemotherapy. The primary endpoint of the study was 1-year progression-free survival.Results. The study included 70 patients with GTD, 21 (30 %) patients received low-dose induction chemotherapy. In this group, more patients had ECOG performance status ≥2, clinically significant bleeding, or central nervous system metastases. With median follow-up of 54.6 months, 1-year progression-free survival was 81 % in the low-dose induction chemotherapy group and 90 % in the control group, the differences were not statistically significant (hazard ratio 1.63; 95 % confidence interval 0.46–5.80; p = 0.447). Complete β-hCG response was noted in 16 (77 %) patients in the lowdose induction group and 43 (88 %) patients in control group (p = 0.231). Three-year overall survival rates were 95 % and 98 %, respectively.Conclusion. The results of this retrospective study show no differences in survival of patients with high-risk and ultra-highrisk GTD receiving low-dose induction chemotherapy. In treatment of patients with high risks of complications due to tumor process and/or drug therapy, low-risk induction chemoterhapy should be considered as an option
- Open Access
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 80-90
The Use of Transarterial Chemoembolization in the Treatment of Patients with Uveal Melanoma with Isolated Metastatic Liver Disease.
Purpose: To evaluate the tolerability and efficacy of transarterial chemoembolization (TACE) in the treatment of patients with metastatic liver disease from uveal melanoma. Materials and methods: From 2000 to 2024, 131 patients with uveal melanoma underwent liver TACE for metastatic liver disease at the N.N. Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health. The treatment was carried out for multiple bilobar liver disease (110 patients) and solitary/single liver metastases (21 patients). A total of 283 TACEs were performed. The duration of observation after TACE ranged from 1 to 152 months. The median observation was 11 months. Results: TACE was technically successful in 100 % of cases. Postembolization syndrome of varying severity was observed in 82.4 %. Mortality 0 %. Local response (according to mRECIST) was observed in 75/131 (57.2 %) patients. Overall survival (OS) (n=131) was: 1-year — 78.5 %, 2-year — 47 %, %, 3-year — 17 %. Median overall survival was 23 months. In the group of patients who received only TACE (n=29): 1-year OS — 66 %, 2-year OS — 27 %, 3-year OS — 13 %. In the TACE + additional treatment group (n=102) — 1-year OS — 82.2 %, 2-year OS — 50.3 %, 3-year OS — 23.7 %. Conclusions: TACE is a safe treatment option for patients with uveal melanoma with different volumes of liver metastases. Local response in slightly more than half of patients indicates the need for a more rigorous definition of indications for this intervention. Ourresults with TACE indicate the need for further research to determine the optimal timing of the combination of regional interventional treatment with systemic drug therapy, surgery, and liver chemoperfusion.
- 29 June 2025
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 8 (2) , 80-90
Open AccessThe Use of Transarterial Chemoembolization in the Treatment of Patients with Uveal Melanoma with Isolated Metastatic Liver Disease.
Purpose: To evaluate the tolerability and efficacy of transarterial chemoembolization (TACE) in the treatment of patients with metastatic liver disease from uveal melanoma. Materials and methods: From 2000 to 2024, 131 patients with uveal melanoma underwent liver TACE for metastatic liver disease at the N.N. Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health. The treatment was carried out for multiple bilobar liver disease (110 patients) and solitary/single liver metastases (21 patients). A total of 283 TACEs were performed. The duration of observation after TACE ranged from 1 to 152 months. The median observation was 11 months. Results: TACE was technically successful in 100 % of cases. Postembolization syndrome of varying severity was observed in 82.4 %. Mortality 0 %. Local response (according to mRECIST) was observed in 75/131 (57.2 %) patients. Overall survival (OS) (n=131) was: 1-year — 78.5 %, 2-year — 47 %, %, 3-year — 17 %. Median overall survival was 23 months. In the group of patients who received only TACE (n=29): 1-year OS — 66 %, 2-year OS — 27 %, 3-year OS — 13 %. In the TACE + additional treatment group (n=102) — 1-year OS — 82.2 %, 2-year OS — 50.3 %, 3-year OS — 23.7 %. Conclusions: TACE is a safe treatment option for patients with uveal melanoma with different volumes of liver metastases. Local response in slightly more than half of patients indicates the need for a more rigorous definition of indications for this intervention. Ourresults with TACE indicate the need for further research to determine the optimal timing of the combination of regional interventional treatment with systemic drug therapy, surgery, and liver chemoperfusion.
- Open Access
- 29 March 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (1) , 41-61
Magnetic Resonance Imaging in Objective Response Evaluation in Klatskin Tumor Patients after Endobiliary Photodynamic Therapy
Purpose: Visualization of periductal infiltrative hilar cholangiocarcinomas in general and their changes in response to endobiliary photodynamic therapy (PDT) in particular is not an easy diagnostic task because of their small size, infiltrative growth pattern, and absence of clearly circumscribed margins with adjacent tissue. This caused most researchers to give up the study of criteria for objective response to locoregional treatment, and to use only the survival rate as performance criteria. The aim of this study is to determine the criteria of objective response in Klatskin tumor after PDT based on the analysis of preand postoperative MRI.Material and methods: The study covered 42 patients (26 male (62 %) and 16 female (38 %)) with morphologically verified Klatskin tumor aged 21-76 (median 55) after 104 sessions (from 1 to 10, median 2) of percutaneous endobiliary PDT over the period of 2007-2020. All patients had percutaneous transhepatic or intraoperative drainage of bile ducts from 1 week to 2 years before PDT. Chlorine photosensitizers were used for PDT. The LAHTA-MILON programmable laser unit with 662 nm wavelength was used for photo-irradiation. The specific dose varied from 4.6 to 232,2 J/cm2 (median 29) and the total dose was 64.6-3890 J (median 950), depending on the extent of lesion and the patient’s tolerance to interventions. 220 abdominal MRI were done at various times before and after PDT. Preoperative MRI were completed 1-101 days (median 13.5 days) before the intervention. Postoperative MRI scans were split into groups based on the time following the intervention: 1) after 1–5 days, 2) after 2 months, 3) after 3 months, and 4) after 4 months. Examinations were carried out with the Siemens Magnetom Avanto/Espree 1.5 Tesla MRI scanner. To compare the indicators at different times, the Kruskal–Wallis test was used, p < 0.05 were considered significant.Results: As a result of the analysis, the following statistically significant changes in the Klatskin tumor after PDT were obtained at various times: the largest transverse size of the tumor infiltrate decrease at the proximal hepaticocholedochus level 1 month after PDT; the infiltrate longitudinal size increase at the bile ducts confluence level 4 month after PDT; T2-WI signal intensity increase at the photodynamic area in 1–5 days after PDT; T1-WI signal intensity decrease in various contrasting phases at the photodynamic area in 1–5 days after PDT; ADC signal intensity increase at the photodynamic and conditionally healthy tissues areas 1 month after PDT; T1-WI signal intensity increase in venous and delayed contrasting phases at the photodynamic area 1 month after PDT; T1-WI signal intensity decrease in porto-venous and delayed contrasting phases at the photodynamic area 2 month after PDT; ADC signal intensity decrease at conditionally healthy tissues 4 month after PDT.Conclusion: Changes in MR signal intensity after endobiliary PDT with different pulse sequences (DWI + ADC, T2-WI with and without suppression of signal from adipose tissue, T1-WI before and after intravenous injection of contrast agent in 4 phases of contrasting) in pathological and conditionally healthy intraand periductal tissues and the tumor dimensions (largest crosssectional dimensions and thickness measured in axial and coronal projections in T2-WI) may be used as the criteria of objective response. Determination in the early postoperative period of periductal segments in the area of photodynamic treatment that do not accumulate contrast agent is the most informative, displayable and convenient for practical use criterion of objective response indicating the ischemia of tumor tissue.
- 29 March 2024
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 7 (1) , 41-61
Open AccessMagnetic Resonance Imaging in Objective Response Evaluation in Klatskin Tumor Patients after Endobiliary Photodynamic Therapy
Purpose: Visualization of periductal infiltrative hilar cholangiocarcinomas in general and their changes in response to endobiliary photodynamic therapy (PDT) in particular is not an easy diagnostic task because of their small size, infiltrative growth pattern, and absence of clearly circumscribed margins with adjacent tissue. This caused most researchers to give up the study of criteria for objective response to locoregional treatment, and to use only the survival rate as performance criteria. The aim of this study is to determine the criteria of objective response in Klatskin tumor after PDT based on the analysis of preand postoperative MRI.Material and methods: The study covered 42 patients (26 male (62 %) and 16 female (38 %)) with morphologically verified Klatskin tumor aged 21-76 (median 55) after 104 sessions (from 1 to 10, median 2) of percutaneous endobiliary PDT over the period of 2007-2020. All patients had percutaneous transhepatic or intraoperative drainage of bile ducts from 1 week to 2 years before PDT. Chlorine photosensitizers were used for PDT. The LAHTA-MILON programmable laser unit with 662 nm wavelength was used for photo-irradiation. The specific dose varied from 4.6 to 232,2 J/cm2 (median 29) and the total dose was 64.6-3890 J (median 950), depending on the extent of lesion and the patient’s tolerance to interventions. 220 abdominal MRI were done at various times before and after PDT. Preoperative MRI were completed 1-101 days (median 13.5 days) before the intervention. Postoperative MRI scans were split into groups based on the time following the intervention: 1) after 1–5 days, 2) after 2 months, 3) after 3 months, and 4) after 4 months. Examinations were carried out with the Siemens Magnetom Avanto/Espree 1.5 Tesla MRI scanner. To compare the indicators at different times, the Kruskal–Wallis test was used, p < 0.05 were considered significant.Results: As a result of the analysis, the following statistically significant changes in the Klatskin tumor after PDT were obtained at various times: the largest transverse size of the tumor infiltrate decrease at the proximal hepaticocholedochus level 1 month after PDT; the infiltrate longitudinal size increase at the bile ducts confluence level 4 month after PDT; T2-WI signal intensity increase at the photodynamic area in 1–5 days after PDT; T1-WI signal intensity decrease in various contrasting phases at the photodynamic area in 1–5 days after PDT; ADC signal intensity increase at the photodynamic and conditionally healthy tissues areas 1 month after PDT; T1-WI signal intensity increase in venous and delayed contrasting phases at the photodynamic area 1 month after PDT; T1-WI signal intensity decrease in porto-venous and delayed contrasting phases at the photodynamic area 2 month after PDT; ADC signal intensity decrease at conditionally healthy tissues 4 month after PDT.Conclusion: Changes in MR signal intensity after endobiliary PDT with different pulse sequences (DWI + ADC, T2-WI with and without suppression of signal from adipose tissue, T1-WI before and after intravenous injection of contrast agent in 4 phases of contrasting) in pathological and conditionally healthy intraand periductal tissues and the tumor dimensions (largest crosssectional dimensions and thickness measured in axial and coronal projections in T2-WI) may be used as the criteria of objective response. Determination in the early postoperative period of periductal segments in the area of photodynamic treatment that do not accumulate contrast agent is the most informative, displayable and convenient for practical use criterion of objective response indicating the ischemia of tumor tissue.
- 12 February 2024
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 2,p. 14-23
Surgical treatment and prognostic factors in perihilar tumors
OBJECTIVE To study the results of surgical treatment in patients with perihilar tumors. MATERIAL AND METHODS We analyzed 98 patients with perihilar tumors who underwent surgery. RESULTS We prefer percutaneous transhepatic biliary drainage (n=58) for jaundice. Retrograde interventions were performed in 18 cases (20.5%), complications grade III—IV were more common (p=0.037) in the last group. Postoperative mortality was 12%. Complications developed in 81 patients (82.7%), grade ≥3 — in 39 (39.8%) cases. Portal vein resection (n=26) increased the incidence of complications grade ≥III (p=0.035) and portal vein thrombosis (p=0.0001). Chemotherapy after surgery was performed in 47 patients (48.0%), photodynamic therapy — in 7 (7.1%) patients. A 5-year overall survival was 28.1%, the median survival — 29 months. R2 resection and/or M1 stage (n=12) significantly worsened the prognosis and overall survival (16.5 vs. 31 months, p=0.0055). Lymph node (LN) lesion, microscopic status (R0 vs. R1) of resection margin, technique of decompression and isolated resection of extrahepatic bile ducts did not affect the prognosis, and we combined appropriate patients (n=72) for analysis. SI resection and excision of ≥6 lymph nodes were independent positive factors for disease-free survival (p=0.042 and p=0.007, respectively). Blood transfusion and high preoperative neutrophil-lymphocyte index (NLI ≥2.15) worsened overall (p=0.009 and p=0.002, respectively) and disease-free survival (p=0.002 and 0.007, respectively). The absence of adjuvant therapy worsened disease-free survival alone (p=0.024). CONCLUSION SI liver resection, adequate lymph node dissection and adjuvant therapy should be used for perihilar tumors. Isolated resection of extrahepatic bile ducts is permissible in some cases. Blood transfusion and NLI ≥2.15 are independent negative prognostic factors.
- 12 February 2024
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 2,p. 14-23
Surgical treatment and prognostic factors in perihilar tumors
OBJECTIVE To study the results of surgical treatment in patients with perihilar tumors. MATERIAL AND METHODS We analyzed 98 patients with perihilar tumors who underwent surgery. RESULTS We prefer percutaneous transhepatic biliary drainage (n=58) for jaundice. Retrograde interventions were performed in 18 cases (20.5%), complications grade III—IV were more common (p=0.037) in the last group. Postoperative mortality was 12%. Complications developed in 81 patients (82.7%), grade ≥3 — in 39 (39.8%) cases. Portal vein resection (n=26) increased the incidence of complications grade ≥III (p=0.035) and portal vein thrombosis (p=0.0001). Chemotherapy after surgery was performed in 47 patients (48.0%), photodynamic therapy — in 7 (7.1%) patients. A 5-year overall survival was 28.1%, the median survival — 29 months. R2 resection and/or M1 stage (n=12) significantly worsened the prognosis and overall survival (16.5 vs. 31 months, p=0.0055). Lymph node (LN) lesion, microscopic status (R0 vs. R1) of resection margin, technique of decompression and isolated resection of extrahepatic bile ducts did not affect the prognosis, and we combined appropriate patients (n=72) for analysis. SI resection and excision of ≥6 lymph nodes were independent positive factors for disease-free survival (p=0.042 and p=0.007, respectively). Blood transfusion and high preoperative neutrophil-lymphocyte index (NLI ≥2.15) worsened overall (p=0.009 and p=0.002, respectively) and disease-free survival (p=0.002 and 0.007, respectively). The absence of adjuvant therapy worsened disease-free survival alone (p=0.024). CONCLUSION SI liver resection, adequate lymph node dissection and adjuvant therapy should be used for perihilar tumors. Isolated resection of extrahepatic bile ducts is permissible in some cases. Blood transfusion and NLI ≥2.15 are independent negative prognostic factors.
- Open Access
- 15 December 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 53-61
Subcapsular Hepatic Hematoma after the Endoscopic Retrograde Cholangiopancreatography: Clinical Case and Literature Review
Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive procedure to diagnose and treat the biliary tract and pancreas’ diseases. We would like to present a clinical case of a 66yearold patient, who underwent ERCP due to obstructive jaundice complicated by the subcapsular hematoma, 11.6×4.7×13.4 cm in size according to the computed tomography (CT), and by the leftsided hydrothorax after the hematoma was removed. The patient was successfully treated and discharged on the 15th day after drainage of the pleural cavity. Subcapsular hematoma is a potentially lethal and rare complication that can be treated with a conservative therapy, if diagnosed at an early stage.
- 15 December 2023
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 6 (4) , 53-61
Open AccessSubcapsular Hepatic Hematoma after the Endoscopic Retrograde Cholangiopancreatography: Clinical Case and Literature Review
Endoscopic retrograde cholangiopancreatography (ERCP) is a minimally invasive procedure to diagnose and treat the biliary tract and pancreas’ diseases. We would like to present a clinical case of a 66yearold patient, who underwent ERCP due to obstructive jaundice complicated by the subcapsular hematoma, 11.6×4.7×13.4 cm in size according to the computed tomography (CT), and by the leftsided hydrothorax after the hematoma was removed. The patient was successfully treated and discharged on the 15th day after drainage of the pleural cavity. Subcapsular hematoma is a potentially lethal and rare complication that can be treated with a conservative therapy, if diagnosed at an early stage.
- Open Access
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 57-67
Preoperative chemotherapy usage experience for intrahepatic cholangiocarcinoma
Purpose of the study was to evaluate the safety and feasibility of preoperative chemotherapy in intrahepatic cholangiocarcinoma (IHCC).Patients and methods. A total of 171 liver resections for IHCC were performed between 2007 and 2021, of which 24 were preceded by preoperative therapy (14.0 %). Systemic therapy was conducted in 11 patients (45.8 %). Regional chemotherapy was provided to 13 patients (54.2 %). In two cases, regional chemotherapy was supplemented with systemic therapy.Results. A significant increase in the proportion of patients with clinical stage IIIb and higher was observed in the group of patients who had received preoperative therapy (83.3 % vs. 35.4 %, p < 0.0001). Complications of preoperative therapy occurred in 45.8 % of patients, with grade three and above complications identified in three patients (12.5 %). The incidence of postoperative complications (37.5 % vs. 42.9 %, p = 0.79), post‑resection liver failure (8.3 % vs. 13.6 %, p = 0.7) and postoperative mortality (4.2 % vs. 3.4 %, p = 0.68) in the preoperative therapy group were similar to those in the control group. The rate of radical resections was also identical, 83 % in both groups (p = 0.8). The relapses rates within the first six months after the surgery were similar: 25 % of patients in both groups (p = 0.62). The median OS reached 36 months in the main group and 32 months in the control one (p = 0.81).Conclusion. Since the main group predominantly included patients with more advanced stages of the disease and yet the treatment resulted in comparable immediate and long‑term outcomes, it can be concluded that preoperative therapy can be justified in patients with IHCC who have factors predisposing to poor prognosis. Randomized trials are necessary to determine the rationality, as well as the type and regimen of preoperative therapy to be used in patients with IHCC.
- 26 March 2023
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 10 (1) , 57-67
Open AccessPreoperative chemotherapy usage experience for intrahepatic cholangiocarcinoma
Purpose of the study was to evaluate the safety and feasibility of preoperative chemotherapy in intrahepatic cholangiocarcinoma (IHCC).Patients and methods. A total of 171 liver resections for IHCC were performed between 2007 and 2021, of which 24 were preceded by preoperative therapy (14.0 %). Systemic therapy was conducted in 11 patients (45.8 %). Regional chemotherapy was provided to 13 patients (54.2 %). In two cases, regional chemotherapy was supplemented with systemic therapy.Results. A significant increase in the proportion of patients with clinical stage IIIb and higher was observed in the group of patients who had received preoperative therapy (83.3 % vs. 35.4 %, p < 0.0001). Complications of preoperative therapy occurred in 45.8 % of patients, with grade three and above complications identified in three patients (12.5 %). The incidence of postoperative complications (37.5 % vs. 42.9 %, p = 0.79), post‑resection liver failure (8.3 % vs. 13.6 %, p = 0.7) and postoperative mortality (4.2 % vs. 3.4 %, p = 0.68) in the preoperative therapy group were similar to those in the control group. The rate of radical resections was also identical, 83 % in both groups (p = 0.8). The relapses rates within the first six months after the surgery were similar: 25 % of patients in both groups (p = 0.62). The median OS reached 36 months in the main group and 32 months in the control one (p = 0.81).Conclusion. Since the main group predominantly included patients with more advanced stages of the disease and yet the treatment resulted in comparable immediate and long‑term outcomes, it can be concluded that preoperative therapy can be justified in patients with IHCC who have factors predisposing to poor prognosis. Randomized trials are necessary to determine the rationality, as well as the type and regimen of preoperative therapy to be used in patients with IHCC.
- Open Access
- 15 December 2022
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 5 (4) , 96-106
Results of Application of Saturable Microspheres of Domestic Production in Locoregional Endovascular Treatment of Inoperable Patients with Malignant Liver Tumors
Результаты применения насыщаемых микросфер отечественного производства при локорегионарном эндоваскулярном лечении неоперабельных больных со злокачественными опухолями печени
- 15 December 2022
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 5 (4) , 96-106
Open AccessResults of Application of Saturable Microspheres of Domestic Production in Locoregional Endovascular Treatment of Inoperable Patients with Malignant Liver Tumors
Результаты применения насыщаемых микросфер отечественного производства при локорегионарном эндоваскулярном лечении неоперабельных больных со злокачественными опухолями печени
- Open Access
- 22 September 2022
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 5 (3) , 70-77
Neoadjuvant Endobiliary Photodynamic Therapy in Klatskin Tumor Patients before Resection. First Experience
Complete liver and bile ducts resection with negative margins (R0) in the only possible radical treatment of Klatskin tumor. Even after R0 resection, the recurrence rate is as high as 50–76 %. Neoadjuvant endobiliary photodynamic therapy (PDT) may potentially improve their results and longterm survival. The authors present their own first experience of endobiliary PDT performing before liver and bile ducts resection (R0) in Klatskin tumor patient.
- 22 September 2022
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 5 (3) , 70-77
Open AccessNeoadjuvant Endobiliary Photodynamic Therapy in Klatskin Tumor Patients before Resection. First Experience
Complete liver and bile ducts resection with negative margins (R0) in the only possible radical treatment of Klatskin tumor. Even after R0 resection, the recurrence rate is as high as 50–76 %. Neoadjuvant endobiliary photodynamic therapy (PDT) may potentially improve their results and longterm survival. The authors present their own first experience of endobiliary PDT performing before liver and bile ducts resection (R0) in Klatskin tumor patient.
- Open Access
- 29 January 2022
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- No. 1,p. 89-98
Two approaches in the treatment of malignant obstructive jaundice using nitinol stents
The article presents our experience of observing two different approaches for endoscopic retrograde drainage in patients with malignant pathology of the pancreatobiliary zone, complicated by the bile duct obstruction. In one case, in case of dysfunction of the installed uncovered stent as a result of incrustation with bile salts and/or tumor invasion, stent-to-stent restenting was performed. In the second case, if it was impossible to pass the guidewire retrogradely beyond the area of the tumor narrowing, an alternative method was used – bringing it down by percutaneous transhepatic access towards the endoscope to install a retrograde stent delivery system along it using the "Rendezvous" method.
- 29 January 2022
- Published by Reaviz Medical University in Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)
- No. 1,p. 89-98
Open AccessTwo approaches in the treatment of malignant obstructive jaundice using nitinol stents
The article presents our experience of observing two different approaches for endoscopic retrograde drainage in patients with malignant pathology of the pancreatobiliary zone, complicated by the bile duct obstruction. In one case, in case of dysfunction of the installed uncovered stent as a result of incrustation with bile salts and/or tumor invasion, stent-to-stent restenting was performed. In the second case, if it was impossible to pass the guidewire retrogradely beyond the area of the tumor narrowing, an alternative method was used – bringing it down by percutaneous transhepatic access towards the endoscope to install a retrograde stent delivery system along it using the "Rendezvous" method.